



(51) International Patent Classification:

A61K 39/21 (2006.01) A61K 9/127 (2006.01)
A61K 39/39 (2006.01)

(21) International Application Number:

PCT/US2014/045940

(22) International Filing Date:

9 July 2014 (09.07.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/969,905 25 March 2014 (25.03.2014) US

(71) Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY [US/US]; 504 Scott Street, Fort Detrick, Maryland 21702 (US).

(72) Inventors: ALVING, Carl, R.; 7118 Glenbrook Road, Bethesda, Maryland 20814 (US). KIM, Jerome, H.; 8622 Garfield Street, Bethesda, Maryland 20817 (US). RAO,

Mangala; 607 Hyde Road, Silver Spring, Maryland 20902 (US).


(74) Agents: MEYER, Mercedes, K. et al.; Drinker Biddle & Reath LLP, 1500 K Street, N.W., Suite 1100, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: METHODS FOR ENHANCING THE IMMUNOSTIMULATION POTENCY OF ALUMINUM SALT-ADSORBED VACCINES



(57) Abstract: Provided herein are (1) a method of mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)), and (2) the resulting immunogenic composition. The resulting immunogenic composition has an enhanced immunostimulation potency compared with either a composition comprising the uncapsulated immunogen mixed with the L(MPLA) or the aluminum salt-adsorbed immunogen alone.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

CROSS REFERENCE TO RELATED APPLICATIONS

U.S. GOVERNMENT RIGHT

10 **FIELD**

15 BACKGROUND

Aluminum salts are currently used in many vaccines, for example, the vaccines against cervical cancer (HPV), hepatitis, polio, tetanus, diphtheria, and seasonal flu. *See, e.g.,* Baylor et al., 2002, Vaccine 20: S18-S23; *see also* Kristensen, 2012 Summary of Stability data for licensed vaccines, on the Internet at [hypertext transfer protocol://www.path.org/publications/files/TS_vaccine_stability_table.pdf](http://www.path.org/publications/files/TS_vaccine_stability_table.pdf). Although their precise mechanisms of action remain to be fully understood, these adjuvants have been widely used for many decades in licensed human vaccines. They have a longer record of safety and have been administered to humans in billions of doses. *Id.*

1

SUMMARY

Accordingly, there remains a need in the field to develop more potent vaccine formulations. For this, new adjuvants may need to be identified and characterized. Alternatively, such a goal may be achieved by enhancing the immunostimulation potency of the pre-existing aluminum salts-adsorbed vaccines. Provided herein is a method of enhancing immunostimulation potency of an aluminum salt-adsorbed immunogen by mixing a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)) composition with the aluminum salt-adsorbed immunogen to obtain a composition having enhanced immunostimulation potency. Also described are compositions produced by such methods. For example, provided herein is a HIV vaccine composition comprising aluminum hydroxide gel-adsorbed gp120 protein mixed with L(MPLA), which displays an enhanced immuneresponse, *e.g.*, increased antibody production in immunized subjects.

Accordingly, a method of preparing an immunogenic composition is provided, comprising mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)) to obtain the immunogenic composition in a liquid phase, wherein the aluminum salt-adsorbed immunogen comprising an immunogen absorbed by an aluminum salt. The method may further comprise incubating the aluminum salt-adsorbed immunogen and L(MPLA), upon mixing, at a temperature in the range of about 4 °C to about 37 °C for about 30 minutes to about 24 hours, or preferably about 1 hour to about 12 hours.

The method may result in the immunogenic composition having an enhanced immunostimulation potency compared with the aluminum salt-adsorbed immunogen alone. Additionally or alternatively, the method may result in the immunogenic composition has an enhanced immunostimulation potency compared with the uncapsulated immunogen mixed with L(MPLA).

In one aspect, the L(MPLA) may be lyophilized. The L(MPLA) may comprise about 50 mM to about 150 mM phospholipids, and the dry weight ratio between the aluminum and the MPLA within the immunogenic composition may be in the range of about 1:110 to about 85:3. The dry weight ratio between the aluminum and the immunogen within the aluminum salt-adsorbed immunogen may be in the range of about 1:30 to about 85:1.

In another aspect, the aluminum salt may be aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, or any combination thereof. The aluminum salt-adsorbed immunogen may be an aluminum salt-adsorbed vaccine for *Haemophilus influenza* type b, hepatitis A, hepatitis B, human papillomavirus, pandemic influenza, Japanese encephalitis, meningococcus, pneumococcus, rabies, tetanus toxoid, diphtheria, tetanus, pertussis, polio, Lyme disease, anthrax, typhoid, or combinations thereof.

In a further aspect, the aluminum salt-adsorbed immunogen may comprise aluminum salt-adsorbed HIV-1 protein gp120. Preferably, the aluminum salt in the aluminum salt-adsorbed HIV-1 protein gp120 is aluminum hydroxide.

Also provided is the immunogenic composition prepared by mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)). The immunogenic composition may further comprise a physiologically acceptable vehicle. The immunogenic composition may comprise an aluminum hydroxide-adsorbed HIV-1 protein gp120 as the aluminum salt-adsorbed immunogen, and a single dose of the immunogenic composition may further comprise: (1) about 10 µg to about 600 µg of gp120 protein; (2) about 20 µg to about 850 µg of aluminum; and (3) about 30 µg to about 2.2 mg of L(MPLA) comprising about 50 mM to about 150 mM phospholipids.

A method of enhancing an immunostimulation potency of an aluminum salt-adsorbed immunogen is also provided, comprising mixing L(MPLA) to the aluminum salt-adsorbed immunogen to obtain an immunogenic composition in a liquid phase, wherein the aluminum salt-adsorbed immunogen comprising an immunogen adsorbed by an aluminum salt. The method may further comprise incubating the aluminum salt-adsorbed immunogen and L(MPLA), upon mixing, at a temperature in the range of about 4 °C to about 37 °C for about 30 minutes to about 24 hours, or preferably about 1 hour to about 12 hours.

In one aspect, the L(MPLA) may be lyophilized. The L(MPLA) may comprise about 50 mM to about 150 mM phospholipids, and the dry weight ratio between the aluminum and the MPLA within the immunogenic composition may be in the range of about 1:110 to about 85:3. The dry weight ratio between the aluminum and the immunogen within the aluminum salt-adsorbed immunogen may be in the range of about 1:30 to about 85:1.

In another aspect, the aluminum salt may be aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, or any combination thereof. The aluminum salt-adsorbed immunogen may be an aluminum salt-adsorbed vaccine for *Haemophilus influenza* type b, hepatitis A, hepatitis B, human papillomavirus, pandemic influenza, Japanese encephalitis, meningococcus, pneumococcus, rabies, tetanus toxoid, diphtheria, tetanus, pertussis, polio, Lyme disease, anthrax, typhoid, or combinations thereof.

In a further aspect, the aluminum salt-adsorbed immunogen may comprise aluminum salt-adsorbed HIV-1 protein gp120. Preferably, the aluminum salt in the aluminum salt-adsorbed HIV-1 protein gp120 is aluminum hydroxide.

Also provided is a use of a L(MPLA) composition to enhance immunostimulation potency of an aluminum salt-adsorbed immunogen.

BRIEF DESCRIPTION OF THE DRAWING

The accompanying drawing is incorporated into the specification and provide non-limiting illustration of various embodiments.

FIG. 1 illustrates the resulting complex produced by mixing AIDSVAX® (an experimental HIV vaccine comprising HIV-1 gp120) with L(MPLA) as described in Example 1.

DETAILED DESCRIPTION

1. Definitions

An “immunogen” is an agent capable of inducing humoral and/or cell-mediated immune response. The immunogen as described herein can be an antigen or an inactivated pathogen. An immunogenic composition as described herein can be, for example, a vaccine formulation.

“Aluminum salts” used for adjuvants can comprise aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate (alum), or any combination thereof. In the vaccine field, all aluminum salt adjuvants, regardless of exact chemical composition, are commonly referred to informally as “alum.”

“Liposomes” as used herein refer to closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be unilamellar vesicles possessing a single membrane bilayer or multilamellar vesicles with multiple membrane bilayers, each separated from the next by an aqueous layer. The structure of the resulting

membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hydrophilic (polar) heads orient towards the aqueous phase. Liposomes, as they are ordinarily used, consist of smectic mesophases, and can consist of either phospholipid or nonphospholipid smectic mesophases. Smectic mesophase is most accurately described by Small, HANDBOOK OF LIPID RESEARCH, Vol. 4, Plenum, NY, 1986, pp. 49-50. According to Small, “[w]hen a given molecule is heated, instead of melting directly into an isotropic liquid, it may instead pass through intermediate states called mesophases or liquid crystals, characterized by residual order in some directions but by lack of order in others ... In general, the molecules of liquid crystals are somewhat longer than they are wide and have a polar or aromatic part somewhere along the length of the molecule. The molecular shape and the polar-polar, or aromatic, interaction permit the molecules to align in partially ordered arrays ... These structures characteristically occur in molecules that possess a polar group at one end. Liquid crystals with long-range order in the direction of the long axis of the molecule are called smectic, layered, or lamellar liquid crystals ... In the smectic states the molecules may be in single or double layers, normal or tilted to the plane of the layer, and with frozen or melted aliphatic chains.”

Lipid A is a set of complex, heavily acylated and amidated diglucosamine diphosphate molecules and is the lipid moiety common to all lipopolysaccharides (LPS; also known as endotoxin) from Gram-negative bacteria. LPS covers virtually the entire outer surface of all Gram-negative bacteria, and lipid A anchors the LPS into the outer lipid surface of the bacterium. The O-polysaccharide portion of LPS in wild-type smooth bacteria is linked to a relatively conserved core oligosaccharide that is expressed in rough mutants, and this in turn is linked to lipid A through highly conserved 2-keto-3-deoxyoctanoic acid sugars that are unique chemical structures required for bacterial viability and found only in LPS. *See, e.g.*, Alving et al., 2012, Expert Rev. Vaccines 11: 733-44. “Monophosphoryl lipid A” is a lipid A congener in which the glucosamine-1-phosphate group on the polar head group has been removed. Numerous congeners of MPLA also exist.

A “physiologically acceptable vehicle” as used herein refers to a vehicle that is suitable for *in vivo* administration (*e.g.*, oral, transdermal or parenteral administration) or *in vitro* use, *i.e.*, cell culture. Exemplary physiologically acceptable vehicles can

be those physiologically acceptable constituents of liposomes as disclosed in U.S. Patent Nos. 4,186,183 and 4,302,459.

The term “about” as used herein refers to $\pm 15\%$ of the referenced value.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that as used herein, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” includes a plurality of such antibodies and reference to “the dosage” includes reference to one or more dosages and equivalents thereof known to those skilled in the art, and so forth.

“Preferred” and “Preferably” as used herein are to be construed for purposes of claim construction in Europe only. The terms should be read out of or omitted from the construction of the sentences and paragraphs in which they appear for purposes of U.S. claim construction.

15

2. Aluminum Salt-Adsorbed Vaccines

Aluminum salts used for adjuvants can comprise aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate (alum), or any combination thereof. An exemplary list of aluminum salt-adsorbed vaccines is shown below:

20 DTaP (for Diphtheria, Tetanus, and Pertussis vaccine)
 DTP (for Diphtheria, Tetanus, and Pertussis vaccine)
 Hib conjugate (*Haemophilus influenza* type b, Hib)
 Pneumo conjugate (pneumococcal vaccine)
 DTP-Hib (combination vaccine for Diphtheria and *Haemophilus influenza*
 25 type b)
 Hep B-Hib (combination vaccine for Hepatitis B / *Haemophilus influenza* type B)
 Hep B (Hep B stands for hepatitis B)
 DT adsorbed (Diphtheria and tetanus toxoids adsorbed)
 30 T, adsorbed (for Tetanus)
 Td, adsorbed (Td stands for Tetanus and Diphtheria)
 Hep A (for hepatitis A)
 Lyme

Anthrax

Rabies

See Baylor et al., 2002, Vaccine 20: S18-S23. A more expanded list is provided in Kristensen, 2012, Summary of Stability data for licensed vaccines, on the Internet at

5 hypertext transfer

protocol://www.path.org/publications/files/TS_vaccine_stability_table.pdf .

At least 146 licensed vaccines exist currently against single or multiple pathogens have been currently adjuvanted with an aluminum salt. Exemplary vaccines include, but are not limited to, those for *Haemophilus influenza* type b, hepatitis A, hepatitis B, human papillomavirus, pandemic influenza, Japanese encephalitis, meningococcus, pneumococcus, rabies, tetanus toxoid, diphtheria, tetanus, pertussis, polio, Lyme disease, anthrax, typhoid, and combinations thereof. Preferably, the aluminum salt-adsorbed vaccine is provided as an aqueous suspension.

10 The actual amount of the aluminum salt adjuvant in vaccines may vary depending on multiple factors, *e.g.*, the subject (animal versus human, adult versus child) to be immunized and the route of administration. Immunogenic dosages can be determined by those of skill in the art. In the vaccines licensed in the U.S., the amount of aluminum ranges from about 0.125–0.85 mg/dose. *See*, Baylor et al., 2002, Vaccine 20: S18-S23. For human vaccination, the preferable range of the amount of aluminum may range from about 20 µg to about 850 µg per dose of vaccine. The amount of immunogen, most commonly protein antigen, may be in the range of about 1 µg to about 1 mg per dose of vaccine, or preferably about 10 µg to about 600 µg per dose of vaccine.

25 Typically, the immune response by the aluminum salt-adsorbed vaccines can be detected by the presence of antibodies that specifically bind to a particular polypeptide. Methods of detecting antibodies are known to those of skill in the art and include such assays as enzyme-linked immunosorbent assay (ELISA), Enzyme-Linked ImmunoSpot (ELISPOT) assays, Western blot assays, and competition assays.

30 3. **Monophosphoryl lipid A (MPLA)-Containing Liposomes (L(MPLA))**

Liposomes are closed bilayer membranes containing an entrapped aqueous volume. Liposomes may also be unilamellar vesicles possessing a single membrane bilayer or multilamellar vesicles with multiple membrane bilayers, each separated

from the next by an aqueous layer. The structure of the resulting membrane bilayer is such that the hydrophobic (non-polar) tails of the lipid are oriented toward the center of the bilayer while the hydrophilic (polar) heads orient towards the aqueous phase. Suitable hydrophilic polymers for surrounding the liposomes include, without
 5 limitation, PEG, polyvinylpyrrolidone, polyvinylmethylether, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyloxazoline, polyhydroxypropylmethacrylamide, polymethacrylamide, polydimethylacrylamide, polyhydroxypropylmethacrylate, polyhydroxyethylacrylate, hydroxymethylcellulose, hydroxyethylcellulose, polyethyleneglycol, polyaspartamide and hydrophilic peptide
 10 sequences as described in U.S. Patent Nos. 6,316,024; 6,126,966; 6,056,973; and 6,043,094. Liposomes can be made without hydrophilic polymers. Therefore, liposome formulations may or may not contain hydrophilic polymers.

Liposomes may be comprised of any lipid or lipid combination known in the art. For example, the vesicle-forming lipids may be naturally-occurring or synthetic
 15 lipids, including phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, and sphingomyelin as disclosed in U.S. Patent Nos. 6,056,973 and 5,874,104.

The vesicle-forming lipids may also be glycolipids, cerebroside, or cationic
 20 lipids, such as 1,2-dioleoyloxy-3-(trimethylamino)propane (DOTAP); N-[1-(2,3-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1[(2,3,-dioleoyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3 [N--(N',N'-dimethylaminoethane) carbamoyl] cholesterol (DCChol); or
 25 dimethyldioctadecylammonium (DDAB) also as disclosed in U.S. Patent No. 6,056,973. Cholesterol may also be present in the proper range to impart stability to the liposome vesicle, as disclosed in U.S. Patent Nos. 5,916,588 and 5,874,104. Additional liposomal technologies are described in U.S. Patent Nos. 6,759,057; 6,406,713; 6,352,716; 6,316,024; 6,294,191; 6,126,966; 6,056,973; 6,043,094;
 30 5,965,156; 5,916,588; 5,874,104; 5,215,680; and 4,684,479. These described liposomes and lipid-coated microbubbles, and methods for their manufacture. Thus, one skilled in the art, considering both the present disclosure and the disclosures of these other patents could produce a liposome for the purposes of the present

embodiments. For the present embodiments, the liposomes preferably contain 50-150 mM phospholipids.

Any of the above exemplary liposomes would include monophosphoryl Lipid A (MPLA), or could be combined with other liposomes and Lipid A (MPLA). MPLA alone can be toxic to humans and animals. However, when present in liposomes, the toxicity is not detected. *See, e.g.,* Alving et al., 2012, Expert Rev. Vaccines 11: 733-744. Exemplary procedures for preparation of the liposomes with MPLA as described herein are taught at least in Alving et al., 2012, Expert Rev. Vaccines 11: 733-744. MPLA serves as a potent adjuvant and serves to raise the immunogenicity of the liposome and peptides, proteins, or haptens associated with the liposome. For the present embodiments, the amount of MPLA preferably may be in the range of about 30 µg to about 2.2 mg per dose of vaccine.

EXAMPLES

The following examples are provided in order to demonstrate and further illustrate certain representative embodiments and aspect of the present disclosure and are not to be construed as limiting the scope of the specification or claims.

Materials and Methods

Immunization

AIDSVAX® (VaxGen, South San Francisco, Cal., U.S.) is an experimental HIV vaccine comprising the HIV surface glycoprotein gp120 as described in Adis International Ltd., 2003, Drugs R. D. 4: 249-53. L(MPLA) was prepared as described in Wassef et al., 1994, ImmunoMethods 4: 217-22.

AIDSVAX® B/E comprises a mixture of clades B and E HIV gp120 proteins adsorbed to aluminum hydroxide (GSID, South San Francisco, Cal., U.S.). Varying amounts of AIDSVAX® B/E were added to lyophilized vials of L(MPLA), and the mixture was left at 4 °C for 1 hour or at 4 °C overnight. Each vial was swirled to ensure that there were no clumps of the lyophilized material as observed by visual inspection. Test articles (50 µl/mouse) were injected intramuscularly by needle and syringe into 9 groups of female BALB/c mice (6 mice per group) as shown in Table 1 below:

Table 1: Immunization set up

Group	AIDSVAX® B/E Amount μg/dose/50 μl	Al Amount μg/dose/50 μl	L(MPLA) Amount μg/dose/50 μl	Mixing and Immunizing Procedure
1	30	30	0	n/a (not applicable)
2	30	30	9.25	Inject 12 hr after addition of AIDSVAX® BE to lyophilized L(MPLA) vial
3	30	30	9.25	Inject 24-26 hr after addition of AIDSVAX® B/E to lyophilized L(MPLA) vial
4	10	10	0	n/a (not applicable)
5	1	1	0	n/a (not applicable)
6	0.1	0.1	0	n/a (not applicable)
7	10	10	9.25	Inject 24-26 hr after addition of AIDSVAX® B/E to lyophilized L(MPLA) vial
8	1	1	9.25	Inject 24-26 hr after addition of AIDSVAX® B/E to lyophilized L(MPLA) vial
9	0.1	0.1	9.25	Inject 24-26 hr after addition of AIDSVAX® B/E to lyophilized L(MPLA) vial

The amounts of gp120 proteins and aluminum salt, as expressed in Table 1, refer to the dry weight. The resulting mixture is in a liquid phase, wherein the lyophilized L(MPLA) has been spontaneously hydrated given that the aluminum salt-adsorbed gp120 was provided as an aqueous suspension.

Mice were immunized through the intramuscular route on weeks 0, 3, 6, and bled on weeks 0, 2, 4, 6, 8, and 10. Individual serum samples were tested by ELISA for IgG binding antibodies to A244 gp120 and MN gp120 proteins (proteins present in AIDSVAX® B/E) at the time points indicated.

Detection of antibody responses after vaccination by ELISA

Ninety-six well U-bottom ELISA plates were coated overnight at 4 °C with 100 μl/well of purified A244 or MN proteins provided by Global Solutions for Infectious Diseases (South San Francisco, Cal., U.S.) as described in Karasavvas et al.,

2012, AIDS Res. Hum. Retroviruses 28: 1444-57. The protein was removed and each well was blocked with 250 µl of blocking buffer (Phosphate buffered saline (PBS) containing 0.5% casein and 0.5% bovine serum albumin(BSA), pH 7.4) overnight at 4 °C. The plates were washed twice with PBS containing 0.1% Tween-20, pH 7.4
5 (PBS-T), and 100 µl of serum (1:200 dilution) was added to wells in triplicate and then serially diluted two-fold in blocking buffer. The plates were incubated for 2 hours at room temperature and washed four times with PBS-T. The plates were washed and 100 µl of horseradish peroxidase-conjugated sheep anti-mouse IgG (BindingSite, San Diego, Cal., U.S.) diluted 1:1000 in the blocking buffer were added
10 to each well. The plates were incubated for 1 hour at room temperature, washed, and 100 µl of ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) substrate (KPL, Gaithersburg, Md., U.S.) were added to each well. The plates were then incubated for 1 hour in the dark at room temperature. The absorbance was read at 405 nm on an ELISA plate reader.

15

Example 1 – Addition of L(MPLA) to aluminum hydroxide-adsorbed HIV-1 gp120 (AIDSVAX® B/E) resulted in increased antibody titers

The adjuvant field has evolved a number of adjuvant candidates, and the most effective of these are administered as adjuvant formulations that include more than
20 one adjuvant or carrier molecule. In an Acquired Immunodeficiency Syndrome (AIDS) Vaccine Evaluation Group Study 015 (AVEG015), seven adjuvants (including aluminum hydroxide, identified as “alum”) were compared for safety and for the ability to induce immune responses in humans against HIV-1 envelope protein gp120. McElrath, 1995, Semin. Cancer Biol. 6: 375-85. It was observed by McElrath
25 during the AVEG015 study that alum-adsorbed liposomes containing encapsulated gp120 and monophosphoryl lipid A outperformed alum-adsorbed gp120 and performed as well, or better than, each of the other adjuvants for inducing an immune response to gp120, and that these same alum-adsorbed liposomes exhibited low levels of local and systemic toxicity equivalent to the low levels of alum-adsorbed gp120
30 alone.

Given the McElrath's results, the following experiments were conducted to evaluate the effects of directly mixing alum-adsorbed gp120 with liposomes

containing MPLA, *i.e.*, gp120 is not encapsulated within the liposomes (FIG. 1), different from what is described in McElrath. For this, female BALB/c mice of 6-8 weeks were immunized as described in the Materials and Methods, as illustrated in Table 1. Blood samples were collected for each mouse at weeks 0, 2, 4, 6, 8, and 10.

- 5 ELISA was performed to determine the titers of antibodies in the sera as described in the Materials and Methods above. The arithmetic mean and the standard error of the mean (SEM) for each group at each time point were calculated, and the data are compiled in Table 2 below:

Table 2: Compiled antibody titers

Group	2 weeks post 1 st immunization		1 week post 2nd immunization		3 weeks post 2nd immunization		2 weeks post 3rd immunization		4 weeks post 3rd immunization	
	A244	MN	A244	MN	A244	MN	A244	MN	A244	MN
1	833	1,467	34,133	115,200	20,267	68,267	78,933	955,733	119,467	750,933
	±	±	±	±	±	±	±	±	±	±
	182	382	7,867	30,826	3,473	27,782	27,733	136,533	28,558	195,486
2	2,267	4,267	68,267	136,533	59,733	115,200	315,733	887,467	256,000	887,467
	±	±	±	±	±	±	±	±	±	±
	434	675	10,794	21,588	8,533	59,764	110,933	164,408	51,200	164,408
3	2,800	4,533	59,733	71,680	64,000	59,733	163,840	1,058,133	187,733	614,400
	±	±	±	±	±	±	±	±	±	±
	820	868	8,533	12,541	12,800	29,313	25,083	271,784	48,871	91,589
4	480	750	16,533	34,880	12,267	9,067	42,667	290,133	46,933	375,467
	±	±	±	±	±	±	±	±	±	±
	136	309	7,681	19,015	4,538	1,736	5,397	116,504	4,267	107,939
5			3,633	2,467	3,867	3,333	14,933	104,533	19,200	113,067
	ND	ND	±	±	±	±	±	±	±	±
			1,900	1,266	2,004	1,982	3,570	33,771	2,862	32,113
6	200	800	200		867	267	1,840	9,067	4,467	11,233
	±	±	±	ND	±	±	±	±	±	±
	0	0	0		405	123	588	2,397	1,883	3,652
7	2,200	3,067	59,733	145,100	55,467	98,133		324,267		324,267
	±	±	±	±	±	±	N/A	±	N/A	±
	482	784	8,533	58,282	10,275	33,972		107,126		55,565
8	467	1,100	41,600	55,467	10,933	20,267		256,000		375,467
	±	±	±	±	±	±	N/A	±	N/A	±
	111	300	14,382	10,275	3,417	3,473		51,200		97,742
9	800	200	1,800	960	10,680	17,933		27,733		38,400
	±	±	±	±	±	±	N/A	±	N/A	±
	0	0	503	299	10,133	16,901		7,692		8,095

10 N/A: not available; ND: not detectable by ELISA.

According to the results in Table 2, addition of L(MPLA) to AIDSVAX® B/E resulted in a dramatic increase in IgG antibodies specific to A244 and MN. The multi-fold increase varies between 2.7-12-fold increase depending upon the weeks post immunization and the amount of the antigen used during immunization.

5 Immunization of mice with 1 µg of AIDSVAX® B/E containing L(MPLA) induced antibody responses that were equivalent to antibody responses induced after immunization of mice with 10 µg of AIDSVAX® B/E lacking the L(MPLA). Thus, a smaller dose of antigen (dose sparing of antigen) induced similar responses when L(MPLA) was also present. In all cases, immunization of mice with AIDSVAX®
10 B/E containing L(MPLA) showed higher antibody titers to both A244 and MN proteins when compared to AIDSVAX® B/E alone. Additionally, there appeared to be no difference whether the addition of AIDSVAX® B/E to the lyophilized L(MPLA) was carried out for 1 hour or overnight, because the antibody titers appeared similar.

15 The method of mixing an aluminum salt-adsorbed vaccine, such as anyone of those taught in Baylor et al., 2002 and Kristensen, 2012, with the L(MPLA) described here is believed to enhance the immunostimulation potency of each vaccine composition, not just the vaccine composition exemplified. The methods described herein may enable a greater ease of utilizing liposomal MPLA as an adjuvant for a
20 premade aluminum salt-adsorbed protein vaccine.

The present finding, *i.e.*, the enhanced immunostimulation potency by mixing an aluminum salt-adsorbed vaccine with L(MPLA), is surprising. It was known that the presence of an aluminum salt adjuvant could disrupt liposomes and cause structural changes in the liposomal membrane, ultimately resulting in a reduced
25 immune response. See U.S. Patent No. 5,820,880. Additionally, the reasons for the disruption of the liposomes by aluminum salts remain unclear. Accordingly, those of skill in the art likely would have been discouraged from mixing any aluminum salt-adsorbed vaccine with L(MPLA).

WHAT IS CLAIMED IS:

Claim 1. A method of preparing an immunogenic composition comprising mixing an aluminum salt-adsorbed immunogen with a monophosphoryl lipid A (MPLA)-containing liposome (L(MPLA)) to obtain the immunogenic
5 composition in a liquid phase, wherein the aluminum salt-adsorbed immunogen comprising an immunogen absorbed by an aluminum salt.

Claim 2. The method of claim 1 further comprising incubating the aluminum salt-adsorbed immunogen and L(MPLA), upon mixing, at a temperature in
10 the range of about 4 °C to about 37 °C for about 30 minutes to about 24 hours.

Claim 3. The method of claim 1 or claim 2, wherein the L(MPLA) is lyophilized.

15 Claim 4. The method of anyone of the proceeding claims, wherein the L(MPLA) comprises about 50 mM to about 150 mM phospholipids, and wherein the dry weight ratio between the aluminum and the MPLA within the immunogenic composition is in the range of about 1:110 to about 85:3.

20 Claim 5. The method of anyone of the proceeding claims, wherein the dry weight ratio between the aluminum and the immunogen within the aluminum salt-adsorbed immunogen is in the range of about 1:30 to about 85:1.

Claim 6. The method of anyone of the proceeding claims, wherein the
25 aluminum salt is aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, or any combination thereof.

Claim 7. The method of anyone of the proceeding claims, wherein the aluminum salt-adsorbed immunogen is an aluminum salt-adsorbed vaccine for
30 *Haemophilus influenza* type b, hepatitis A, hepatitis B, human papillomavirus, pandemic influenza, Japanese encephalitis, meningococcus, pneumococcus, rabies, tetanus toxoid, diphtheria, tetanus, pertussis, polio, Lyme disease, anthrax, typhoid, or combinations thereof.

Claim 8. The method of anyone of claims 1 to 6, wherein the aluminum salt-adsorbed immunogen comprises aluminum salt-adsorbed HIV-1 protein gp120.

5 Claim 9. The method of anyone of claims 1-6 and 8, wherein the aluminum salt is aluminum hydroxide.

Claim 10. The method of anyone of the proceeding claims, wherein the immunogenic composition has an enhanced immunostimulation potency compared
10 with the aluminum salt-adsorbed immunogen alone.

Claim 11. The method of anyone of the proceeding claims, wherein the immunogenic composition has an enhanced immunostimulation potency compared with the uncapsulated immunogen mixed with L(MPLA).
15

Claim 12. The immunogenic composition prepared by the method of anyone of the proceeding claims.

Claim 13. The immunogenic composition of claim 12, further comprising
20 a physiologically acceptable vehicle.

Claim 14. The immunogenic composition of claim 12 or claim 13, wherein the aluminum salt-adsorbed immunogen is an aluminum hydroxide-adsorbed HIV-1 protein gp120, and wherein a single dose of the immunogenic composition
25 further comprises:

about 10 µg to about 600 µg of gp120 protein;

about 20 µg to about 850 µg of aluminum; and

about 30 µg to about 2.2 mg of L(MPLA) comprising about 50 mM to about
150 mM phospholipids.
30

Claim 15. A method of enhancing an immunostimulation potency of an aluminum salt-adsorbed immunogen comprising mixing L(MPLA) to the aluminum salt-adsorbed immunogen to obtain an immunogenic composition in a liquid phase,

wherein the aluminum salt-adsorbed immunogen comprising an immunogen adsorbed by an aluminum salt.

Claim 16. The method of claim 15 further comprising incubating the
5 aluminum salt-adsorbed immunogen and L(MPLA), upon mixing, at a temperature in the range of about 4 °C to about 37 °C for about 30 minutes to about 24 hours.

Claim 17. The method of claim 15 or claim 16, wherein the L(MPLA) is
10 lyophilized.

Claim 18. The method of anyone of claims 15-17, wherein the L(MPLA) comprises about 50 mM to about 150 mM phospholipids, and wherein the dry weight ratio between the aluminum and the MPLA within the immunogenic composition is in the range of about 1:110 to about 85:3.
15

Claim 19. The method of anyone of claims 15-18, wherein the dry weight ratio between the aluminum and the immunogen within the aluminum salt-adsorbed immunogen is in the range of about 1:30 to about 85:1.

Claim 20. The method of anyone of claims 15-19, wherein the aluminum salt is aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, or any combination thereof.
20

Claim 21. The method of anyone of claims 15-20, wherein the aluminum salt-adsorbed immunogen is an aluminum salt-adsorbed vaccine for *Haemophilus influenza* type b, hepatitis A, hepatitis B, human papillomavirus, pandemic influenza, Japanese encephalitis, meningococcus, pneumococcus, rabies, tetanus toxoid, diphtheria, tetanus, pertussis, polio, Lyme disease, anthrax, typhoid, or combinations thereof.
25


Claim 22. The method of anyone of claims 15-20, wherein the aluminum salt-adsorbed immunogen comprises aluminum salt-adsorbed HIV-1 protein gp120.
30

Claim 23. The method of anyone of claims 15-20 and 22, wherein the aluminum salt is aluminum hydroxide.

Claim 24. Use of a L(MPLA) composition to enhance immunostimulation
5 potency of an aluminum salt-adsorbed immunogen.

1/1

FIG. 1



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2014/045940

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/21 A61K39/39 A61K9/127
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/21292 A1 (SMITHKLINE BEECHAM BIOLOG [BE]; HAUSER PIERRE [BE]; VOET PIERRE [BE];) 29 September 1994 (1994-09-29) page 7, line 13 - line 15 page 8, line 33 - line 36 page 8, line 35 - line 38 page 18; example 6 page 18, line 15 - line 19 page 19, line 13 - line 16 page 19; example 7 -----	1-24
A	WO 94/19013 A1 (SMITHKLINE BEECHAM CORP [US]; SMITHKLINE BEECHAM BIOLOG [BE]; DILLON S) 1 September 1994 (1994-09-01) page 12, line 37 - line 39 ----- -/-	1-24



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 November 2014

Date of mailing of the international search report

25/11/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Malamoussi, A

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2014/045940

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2006/087563 A2 (CHIRON CORP [US]; O'HAGAN DEREK [US] NOVARTIS VACCINES & DIAGNOSTIC [U] 24 August 2006 (2006-08-24) page 14, paragraph 8 - page 15, paragraph 2 -----	1-24
A	THOELEN S ET AL: "A prophylactic hepatitis B vaccine with a novel adjuvant system", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 17-19, 21 March 2001 (2001-03-21), pages 2400-2403, XP027349951, ISSN: 0264-410X [retrieved on 2001-03-21] abstract -----	1-24
A	A. M. DIDIERLAURENT ET AL: "AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 10, 15 November 2009 (2009-11-15), pages 6186-6197, XP055068455, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901474 abstract page 6187, left-hand column, paragraph 3 -----	1-24
A	MANGALA RAO ET AL: "Highly effective generic adjuvant systems for orphan or poverty-related vaccines", VACCINE, vol. 29, no. 5, 27 November 2010 (2010-11-27), pages 873-877, XP055149397, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2010.11.049 abstract -----	1-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/045940

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9421292	A1	29-09-1994	AP 515 A 09-08-1996
		AT 157882 T 15-09-1997	
		AT 204762 T 15-09-2001	
		AU 685443 B2 22-01-1998	
		AU 6426494 A 11-10-1994	
		AU 7541696 A 13-02-1997	
		BR 9405957 A 12-12-1995	
		CN 1119829 A 03-04-1996	
		CZ 9502467 A3 13-03-1996	
		DE 69405551 D1 16-10-1997	
		DE 69405551 T2 26-03-1998	
		DE 69428136 D1 04-10-2001	
		DE 69428136 T2 02-05-2002	
		DK 0689454 T3 08-12-1997	
		DK 0812593 T3 12-11-2001	
		DZ 1763 A1 17-02-2002	
		EP 0689454 A1 03-01-1996	
		EP 0812593 A1 17-12-1997	
		EP 1175912 A1 30-01-2002	
		ES 2109685 T3 16-01-1998	
		ES 2162139 T3 16-12-2001	
		FI 954514 A 22-09-1995	
		GR 3025483 T3 27-02-1998	
		HK 1011930 A1 23-06-2000	
		HK 1023499 A1 19-04-2002	
		HU 219056 B 28-02-2001	
		IL 109056 A 15-06-1998	
		JP 4028593 B2 26-12-2007	
		JP 4837906 B2 14-12-2011	
		JP H08508722 A 17-09-1996	
		JP 2005015487 A 20-01-2005	
		MA 23143 A1 01-10-1994	
		NO 953759 A 22-09-1995	
		NZ 263538 A 28-10-1996	
		PL 310598 A1 27-12-1995	
		PT 812593 E 30-01-2002	
		SG 48309 A1 17-04-1998	
		SK 117395 A3 06-11-1996	
		US 5776468 A 07-07-1998	
		WO 9421292 A1 29-09-1994	
WO 9419013	A1	01-09-1994	AP 431 A 15-11-1995
		AU 6141094 A 14-09-1994	
		CA 2156525 A1 01-09-1994	
		MA 23118 A1 01-10-1994	
		SI 9400085 A 30-09-1994	
		WO 9419013 A1 01-09-1994	
WO 2006087563	A2	24-08-2006	AU 2006215419 A1 24-08-2006
		BE 1016991 A6 06-11-2007	
		BR PI0608430 A2 29-12-2009	
		CA 2598079 A1 24-08-2006	
		CN 101146551 A 19-03-2008	
		EA 200701743 A1 28-02-2008	
		EP 1850871 A2 07-11-2007	
		JP 2008530195 A 07-08-2008	
		KR 20070110513 A 19-11-2007	
		NZ 560930 A 30-06-2011	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/045940

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		SG 160328 A1	29-04-2010
		US 2009214592 A1	27-08-2009
		WO 2006087563 A2	24-08-2006
		ZA 200707089 A	26-11-2008
